

SmartPA Criteria Proposal

Drug/Drug Class:	Luxturna® Clinical Edit
First Implementation Date:	April 18, 2019
Proposed Date:	June 18, 2020
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of Luxturna® (voretigene neparvovec-rzyl)

Why Issue Selected: Luxturna® is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy, an inherited form of vision loss. Biallelic RPE65 mutation-associated retinal dystrophy affects approximately 1,000 to 2,000 patients in the United States. Mutations in the RPE65 gene lead to reduced or absent concentrations of RPE65 isomerohydrolase activity, blocking the visual cycle and resulting in impaired vision. Vision loss often begins during childhood or adolescence and ultimately progresses to complete blindness. Luxturna is a live, non-replicating adeno-associated virus serotype 2 which has been genetically modified to express the human RPE65 gene; it delivers a normal copy of the gene to the cells of the retina, allowing normal protein production to facilitate phototransduction and restoration of vision loss. Luxturna is administered by subretinal injection performed in each eye on separate days within a close interval, but no fewer than 6 days apart. Premedication with a short course of oral corticosteroids is required prior to administration to prevent potential immune reaction.

Program-Specific Information:

Date Range FFS 4-1-2019 to 3-31-2020				
Drug	Claims	Spend	Cost per vial	Cost per therapy
LUXTURNA VIAL	0	-	\$423,300.00 MAC	\$846,600.00 MAC

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Luxturna® (voretigene neparvovec-rzyl)
- Age range: All appropriate MO HealthNet participants aged 12 months or older

Approval Criteria

SmartPA Clinical Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

- **Prescribed by or in consultation with an ophthalmologist or other specialist in the treated disease state AND**
- Participant has vision loss due to biallelic RPE65 mutation-associated retinal dystrophy as confirmed through genetic testing **AND**
- Participant has viable retinal cells as determined by the provider **AND**
- **Claim does not exceed 2 doses (1 dose per eye) per lifetime**

Denial Criteria

- Therapy will be denied if no approval criteria are met

Required Documentation

Laboratory Results:
MedWatch Form:

X

Progress Notes:
Other:

X

Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)
Rule Type: CE

Default Approval Period

30 days

References

- LUXTURNA (voretigene neparvovec-rzyl) intraocular suspension for subretinal injection [package insert]. Philadelphia, PA: Spark Therapeutics, Inc.; December 2019.
- Clinical Pharmacology. Voretigene Neparvovec: LUXTURNA. Accessed May 13, 2020.